top of page
CET's therapeutic business model is based on a hybrid CD/CMO model based on CET's intellectual property, expertise and capabilities. CET develops and licenses IND-ready or pre-IND assets. CET's platform is directed towards cell therapy, biologics and vaccines. CET has an active collaborative effort with the research program of the John Paul II Medical Research Institute (JP2MRI).
bottom of page